185 related articles for article (PubMed ID: 31386769)
1. The golden hour of polymyxin B hemoperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis.
De Rosa S; Villa G; Ronco C
Artif Organs; 2020 Feb; 44(2):184-186. PubMed ID: 31386769
[TBL] [Abstract][Full Text] [Related]
2. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber.
Aoki H; Kodama M; Tani T; Hanasawa K
Am J Surg; 1994 Apr; 167(4):412-7. PubMed ID: 8179086
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature.
Cruz DN; de Cal M; Piccinni P; Ronco C
Contrib Nephrol; 2010; 167():77-82. PubMed ID: 20519901
[TBL] [Abstract][Full Text] [Related]
4. Sequential Extracorporeal Therapy Collaborative Device and Timely Support for Endotoxic, Septic, and Cardiac Shock: A Case Report.
De Rosa S; Samoni S; Ronco C
Blood Purif; 2020; 49(4):502-508. PubMed ID: 31865323
[TBL] [Abstract][Full Text] [Related]
5. Polymyxin B-immobilized fiber column hemoperfusion removes endotoxin throughout a 24-hour treatment period.
Mitaka C; Fujiwara N; Yamamoto M; Toyofuku T; Haraguchi G; Tomita M
J Crit Care; 2014 Oct; 29(5):728-32. PubMed ID: 24798345
[TBL] [Abstract][Full Text] [Related]
6. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.
Nakamura T; Sugaya T; Koide H
Shock; 2009 May; 31(5):454-9. PubMed ID: 18838948
[TBL] [Abstract][Full Text] [Related]
7. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock.
Mitaka C; Tsuchida N; Kawada K; Nakajima Y; Imai T; Sasaki S
Shock; 2009 Nov; 32(5):478-83. PubMed ID: 19295483
[TBL] [Abstract][Full Text] [Related]
8. Application of polymyxin B convalently immobilized fiber in patients with septic shock.
Suzuki H; Shoji H
Contrib Nephrol; 2010; 166():150-157. PubMed ID: 20473003
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.
Shoji H; Opal SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672437
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of sepsis by extracorporeal elimination of endotoxin using fiber-immobilized polymyxin B].
Aoki H; Tani T; Hanasawa K; Shoji H; Kodama M
Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):775-80. PubMed ID: 8377751
[TBL] [Abstract][Full Text] [Related]
11. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
Dellinger RP; Bagshaw SM; Antonelli M; Foster DM; Klein DJ; Marshall JC; Palevsky PM; Weisberg LS; Schorr CA; Trzeciak S; Walker PM;
JAMA; 2018 Oct; 320(14):1455-1463. PubMed ID: 30304428
[TBL] [Abstract][Full Text] [Related]
12. The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin B-immobilized fiber column in patients with septic shock.
Shimizu T; Obata T; Sonoda H; Akabori H; Tabata T; Eguchi Y; Endo Y; Tani T
Transfus Apher Sci; 2013 Dec; 49(3):499-503. PubMed ID: 23683501
[TBL] [Abstract][Full Text] [Related]
13. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity.
Kojika M; Sato N; Yaegashi Y; Suzuki Y; Suzuki K; Nakae H; Endo S
Ther Apher Dial; 2006 Feb; 10(1):12-8. PubMed ID: 16556131
[TBL] [Abstract][Full Text] [Related]
14. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study.
Lee WY; Kim HJ; Kim EY
Sci Rep; 2021 Dec; 11(1):24132. PubMed ID: 34916567
[TBL] [Abstract][Full Text] [Related]
15. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock.
Mitaka C; Tomita M
Shock; 2011 Oct; 36(4):332-8. PubMed ID: 21654557
[TBL] [Abstract][Full Text] [Related]
16. Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis.
Chang T; Tu YK; Lee CT; Chao A; Huang CH; Wang MJ; Yeh YC
Crit Care Med; 2017 Aug; 45(8):e858-e864. PubMed ID: 28445237
[TBL] [Abstract][Full Text] [Related]
17. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock.
Kase Y; Obata T; Okamoto Y; Iwai K; Saito K; Yokoyama K; Takinami M; Tanifuji Y
Ther Apher Dial; 2008 Oct; 12(5):374-80. PubMed ID: 18937720
[TBL] [Abstract][Full Text] [Related]
18. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial.
Antonelli M; Fumagalli R; Cruz DN; Brienza N; Giunta F
Contrib Nephrol; 2010; 167():83-90. PubMed ID: 20519902
[TBL] [Abstract][Full Text] [Related]
19. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock.
Uriu K; Osajima A; Hiroshige K; Watanabe H; Aibara K; Inada Y; Segawa K; Anai H; Takagi I; Ito A; Kamochi M; Kaizu K
Am J Kidney Dis; 2002 May; 39(5):937-47. PubMed ID: 11979337
[TBL] [Abstract][Full Text] [Related]
20. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
Klein DJ; Foster D; Schorr CA; Kazempour K; Walker PM; Dellinger RP
Trials; 2014 Jun; 15():218. PubMed ID: 24916483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
